Blood typing has become a routine test item of clinical blood transfusion department and clinical laboratory, which includes ABO blood group, Rh blood group, and cross-matching of blood test.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

The Japan Ministry of Health, Labour and Welfare (MHLW), Japan's regulatory agency, has granted approval to the Thermo Fisher Scientific's Oncomine Dx Target Test to be used as a companion diagnostic to identify patients with RET-fusion positive non-small cell lung cancer (NSCLC).

On September 13, 2021, Shanghai Labway Medical Laboratory Co., Ltd. was listed on Shenzhen Stock Exchange (SZSE) ChiNext. Stock code: 688622. The number of new shares publicly issued this time is 48.062 million shares, the issue price is CNY4.17/share, and the opening price is CNY18.25/share.

On September 13, 2021, Guangzhou Hexin Instrument Co., Ltd. was listed on SSE STAR Market. Stock code: 688622. The number of A shares publicly issued this time is 17.5 million shares, the issue price is CNY 17.7/share, and the opening price is CNY 92.11 /share.

Life science company RareCyte said on Thursday that it completed $24 million in financing from both new and existing investors.

PerkinElmer said on Wednesday that it has priced an offering of senior notes totaling $2.3 billion, providing the company with funds to help complete its planned acquisition of BioLegend.

Siemens Healthineers on Thursday announced a collaboration with A1 Life Sciences to offer an evolving portfolio of PCR-based assays for the identification of SARS-CoV-2 mutations and variants.

Roche announced on Thursday that it has entered a share purchase agreement to acquire 100 percent of the outstanding shares of the TIB Molbiol Group.

On September 9, 2021, Agilent successfully delivered the first batch of SureSelect targeted capture probe products produced in China at its Hangzhou production base.

Foundation Medicine announced on Wednesday that it is collaborating with Science 37 to create a home-based clinical trial model for patients who can't travel to clinical trial sites.

Alamar Biosciences said on Wednesday that it has closed an $80 million Series B financing round, bringing its total funding to $110 million.